Genomic Vision appoints Dominique Rémy-Renou as new Chair of the Management Board.

– FRANCE, Bagneux –  Genomic Vision (EPA: GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announced the resignation of Aaron Bensimon as Chairman of the Management Board and the intention of strengthening the Company’s sales momentum by appointing Mrs. Dominique Rémy-Renou as new Chairman of the Management Board.

Mrs. Dominique Rémy-Renou will bring to Genomic Vision over 30 years of experience in the field of life sciences and genetics, where she has held various International Management positions at Applied Biosystems, Fluidigm Corporation and, more recently, Pacific Biosciences. Dominique Rémy-Renou has always successfully contributed to developing sales, her expertise notably including sales, marketing, support, organization and, more broadly, managing people and operations.

Mr. Aaron Bensimon, the founder of the Company, has decided to stand down as Chairman after 16 years to focus, as Managing Director, on the scientific strategy and the management of Research & Development activities. Aaron Bensimon, Doctor of Molecular Biology and the former Director of the Genomic Stability Unit at the Pasteur Institute, is the co-inventor of the DNA molecular combing process.

Mr. Pierre Schwich, previously Investment Director for 3i (Private Equity) and CFO of a number of high-growth listed technology companies, notably in the biotechnology sector (Cellectis, Pharnext), joined the management team of GENOMIC VISION as CFO earlier this year within the framework of the Company’s new development prospects.

Mrs. Isabelle Racamier, Mrs. Elisabeth Jacobs and Mr. Florian Schödel have all stood down.

Mrs. Elisabeth Ourliac, a member of the Supervisory Board since 2015, has been appointed President. Elisabeth Ourliac has brought substantial experience to Genomic Vision given her particularly rich and exemplary career at Airbus, of which she is currently Vice-President Strategy. Her experience notably covers finance, audit and risk management, management of multicultural projects and strategy within an international high-tech environment.

Mr. Stéphane Verdood, a member of the Supervisory Board since 2008, has been appointed Vice-President. Stéphane Verdood, a former consultant in the field of health and biotechnologies, is Managing Partner of Vesalius Biocapital, a longstanding investor in Genomic Vision.

Mrs. Tamar Saraga, a member of the Supervisory Board since 2015, has been appointed to the Audit Committee. Tamar Saraga has experience as a Chief Operating Officer and as a consultant in innovation and cross-border Mergers & Acquisitions for technological companies.

The Supervisory Board of Genomic Vision now has three members, two women and a man, two of whom are independent.

About Genomic Vision

Genomic Vision is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed to high confidence characterization of DNA alteration in the genome. These tools are mainly used for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Based near Paris, in Bagneux, the Company has approximately 30 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.